This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.
Device: CytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
Inclusion Criteria:
- confirmed COVID-19 disease
- refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
- IL6 ≥ 500 ng/l
- Indication for CRRT or ECMO
Exclusion Criteria:
- Liver cirrhosis Child Pugh C
- "do not resuscitate"-order
- expected survival due to comorbidities < 14 days
- pregnancy or breastfeeding
- participation in another interventional trial
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Stefan Kluge, MD, Principal Investigator
University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine